Search

Penney, K. L., J. A. Sinnott, K. Fall, Y. Pawitan, Y. Hoshida, P. Kraft, J. R. Stark, et al. 2011. “MRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer”. J Clin Oncol 29: 2391-6.

Perry, J. A., A. Kiezun, P. Tonzi, E. M. Van Allen, S. L. Carter, S. C. Baca, G. S. Cowley, et al. 2014. “Complementary Genomic Approaches Highlight the PI3K/MTOR Pathway As a Common Vulnerability in Osteosarcoma”. Proc Natl Acad Sci U S A 111: E5564-73.

Savage, K. J., S. Monti, J. L. Kutok, G. Cattoretti, D. Neuberg, L. Leval, P. Kurtin, et al. 2003. “The Molecular Signature of Mediastinal Large B-Cell Lymphoma Differs from That of Other Diffuse Large B-Cell Lymphomas and Shares Features With Classical Hodgkin Lymphoma”. Blood 102: 3871-9.

Sboner, A., F. Demichelis, S. Calza, Y. Pawitan, S. R. Setlur, Y. Hoshida, S. Perner, et al. 2010. “Molecular Sampling of Prostate Cancer: A Dilemma for Predicting Disease Progression”. BMC Med Genomics 3: 8.

Setlur, S. R., K. D. Mertz, Y. Hoshida, F. Demichelis, M. Lupien, S. Perner, A. Sboner, et al. 2008. “Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer”. J Natl Cancer Inst 100: 815-25.

Solit, D. B., L. A. Garraway, C. A. Pratilas, A. Sawai, G. Getz, A. Basso, Q. Ye, et al. 2006. “BRAF Mutation Predicts Sensitivity to MEK Inhibition”. Nature 439: 358-62.

Stathias, V., A. M. Jermakowicz, M. E. Maloof, M. Forlin, W. Walters, R. K. Suter, M. A. Durante, et al. 2018. “Drug and Disease Signature Integration Identifies Synergistic Combinations in Glioblastoma”. Nat Commun 9: 5315.

Staunton, J. E., D. K. Slonim, H. A. Coller, P. Tamayo, M. J. Angelo, J. Park, U. Scherf, et al. 2001. “Chemosensitivity Prediction by Transcriptional Profiling”. Proc Natl Acad Sci U S A 98: 10787-92.

Stegmaier, K., J. S. Wong, K. N. Ross, K. T. Chow, D. Peck, R. D. Wright, S. L. Lessnick, A. L. Kung, and T. R. Golub. 2007. “Signature-Based Small Molecule Screening Identifies Cytosine Arabinoside As an EWS/FLI Modulator in Ewing Sarcoma”. PLoS Med 4: e122.

Straussman, R., T. Morikawa, K. Shee, M. Barzily-Rokni, Z. R. Qian, J. Du, A. Davis, et al. 2012. “Tumour Micro-Environment Elicits Innate Resistance to RAF Inhibitors through HGF Secretion”. Nature 487: 500-4.